April 2004
Gut;Apr2004 Supplement 3, Vol. 53, pA105
Academic Journal
6-thioguanine nucleotides (IGN) are considered to be the active cytotoxic metabolite of azathioprine (ALA) although the exact mechanism action of the drug is by no means understood. Patients entering the study were treated with AZA at 2 mg/ kg for at least 6 months. Blood for TGN level was taken at 4, 12, and 24 weeks. This prospective evaluation demonstrates that TGN levels ore not a reliable enough guide to optimal dosing of AZA in inflammatory bowel disease such that it is difficult to envisage their use in routine clinical practice.


Related Articles

  • Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls.  // Inflammatory Bowel Disease Monitor;2010, Vol. 10 Issue 4, p137 

    This study compared psychological functioning and health perceptions in a community IBD patient sample with those in a matched community non-IBD sample of individuals. Overall, the IBD sample had lower psychological wellbeing and mastery, as well as higher distress levels than the non-IBD...

  • Acute distal colitis impairs gastric emptying in rats via an extrinsic neuronal reflex pathway involving the pelvic nerve. De Schepper, H. U.; De Man, I. G.; Van Nassauw, I.; Timmermans, J.-P.; Herman, A. G.; Pelckmans, P. A.; De Winter, B. Y. // Gut;Feb2007, Vol. 56 Issue 2, p195 

    Background and aims: Patients with inflammatory bowel disease often present with abnormal gut motility away from the inflammatory site. We studied remote motility disturbances and their pathophysiology in a rat model of colitis. Methods: Colitis was induced 72 h prior to experiments using...

  • Antibiotics in Inflammatory Bowel Disease: New Choices for an Old Disease. Spirt, Mitchell J. // American Journal of Gastroenterology;Jul1994, Vol. 89 Issue 7, p974 

    A variety of medicines have been used for the treatment of inflammatory bowel disease. Antibiotics have demonstrated promise by improving symptoms and by causing disease remission. The mechanism has never been elucidated, but may he related to elimination of a key pathogen, decreasing the number...

  • Altered Bone Metabolism in Inflammatory Bowel Disease. Bischoff, Stephan C.; Herrmann, Annette; Göke, Michael; Manns, Michael P.; Von zur Mühlen, Alexander; Brabant, Georg // American Journal of Gastroenterology;Jul1997, Vol. 92 Issue 7, p1157 

    A reduced bone mineral density has been reported in inflammatory bowel disease (IBD). Objective: To assess the mechanisms of bone disease in IBD. Methods: We studied in 90 patients (61 with Crohn's disease, 22 with ulcerative colitis, 7 with indeterminate colitis) biochemical markers of bone...

  • Malpractice Risks Associated with Colon Cancer and Inflammatory Bowel Disease. Feld, Andrew D. // American Journal of Gastroenterology;Sep2004, Vol. 99 Issue 9, p1641 

    Analyses of lawsuits against gastroenterologists suggest that the disorders of colon cancer and inflammatory bowel disease are among the more common disorders resulting in malpractice claims, with colon cancer suits receiving some of the highest monetary judgments. Unfortunately, that composite...

  • Heightened Responses to Stressors in Patients with Inflammatory Bowel Disease. Farhadi, Ashkan; Keshavarzian, Ali; van de Kar, Louis D.; Jakate, Shriram; Domm, Aaron; Lei Zhang; Shaikh, Maliha; Banan, Ali; Fields, Jeremy Z. // American Journal of Gastroenterology;Aug2005, Vol. 100 Issue 8, p1796 

    OBJECTIVES: Several studies suggest that stressful situations (stressors) worsen the course of inflammatory bowel disease (IBD), but the mechanism is not known. Based on several lines of evidence, we hypothesized that psychosocial stress activates the brain-gut axis (BGA) and mucosal mast cells...

  • Quality of Health Care in Inflammatory Bowel Disease: Development of a Reliable Questionnaire (QUOTE-IBD) and First Results. Van der Eijk, Ingrid; Sixma, Herman; Smeets, Tamara; Veloso, Fernando Tavarela; Odes, Selwyn; Montague, Sean; Fomaciari, Giovanni; Moum, Björn; Stockbrügger, Reinhold; Russel, Maurice // American Journal of Gastroenterology;Dec2001, Vol. 96 Issue 12, p3329 

    OBJECTIVES: As inflammatory bowel disease is a chronic disorder, usually with an early onset in life, quality of care plays an important role for patients. The aim of this study was to develop a questionnaire to measure quality of care through the eyes of patients with inflammatory bowel...

  • WORM THERAPY: A NEW TREATMENT FOR IBD? Perry, Patrick // Saturday Evening Post;Jul/Aug2004, Vol. 276 Issue 4, p42 

    Addresses questions regarding worm therapy. Status of a study of helminth worm therapy for patients with inflammatory bowel disease; Reasons behind the prevalence of the disease; Definition of helminths. INSET: Probiotics.

  • Role of alkaline phosphatase in colitis in man and rats. A Tuin // Gut;Mar2009, Vol. 58 Issue 3, p379 

    BACKGROUND AND AIMS: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic multifactorial inflammatory bowel diseases (IBDs) with unknown aetiology, but a deregulated mucosal immune response to gut-derived bacterial antigens is thought to be involved. Toll-like receptor ligands,...


Read the Article


Sign out of this library

Other Topics